Details for Patent: 6,956,041
✉ Email this page to a colleague
Summary for Patent: 6,956,041
| Title: | Pyrrolo[2,3-d]pyrimidine compounds |
| Abstract: | A compound of the formula ##STR1## wherein R.sup.1, R.sup.2 and R.sup.3 are as defined above, which are inhibitors of the enzyme protein kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, xeno transplation, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases. |
| Inventor(s): | Blumenkopf; Todd A. (Old Lyme, CT), Flanagan; Mark E. (Gales Ferry, CT), Munchhof; Michael J. (Salem, CT) |
| Assignee: | Pfizer Inc. (New York, NY) |
| Application Number: | 10/640,227 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 6,956,041 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; Use; |
Drugs Protected by US Patent 6,956,041
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 6,956,041
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| African Regional IP Organization (ARIPO) | 1905 | ⤷ Try a Trial | |||
| Argentina | 026534 | ⤷ Try a Trial | |||
| Austria | 257157 | ⤷ Try a Trial | |||
| Austria | 380031 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
